Lakefront Team Spotlight: John Buergenthal, Head of Total Rewards John helps shape the employee experience at Lakefront through compensation, benefits and creating an environment where people feel respected and valued. In this Team Spotlight, John shares his perspective on open communication, fairness and giving employees the opportunity to share in Lakefront’s success. Thanks for your insights, John!

Press Release | Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics Read more: lakefrontbio.com/press-relea…

Please join us in welcoming Joyee Banerjee, MS, MBA, to Lakefront as Vice President, Alliance Management. Joyee brings two decades of experience spanning biotech and pharma. We’re excited for Joyee to bring her experience to help guide our collaborations forward. Welcome to Lakefront, Joyee!

Please join us in welcoming Tony Muchamuel to Lakefront as Senior Director, Toxicology. Tony brings more than 25 years of experience advancing programs through preclinical development. His expertise spans pharmacology, toxicology, and IND-enabling work across autoimmune disease, immunology, and oncology. He will help Lakefront advance our preclinical programs by leading the necessary pharmacology and safety work to move them toward the clinic. Welcome, Tony!

We’re thrilled to welcome Monica Moreno to Lakefront as Senior Director, Clinical Biomarkers. Monica brings more than 12 years of experience in translational medicine and clinical development to the role, with expertise in biomarkers and immunology spanning autoimmune disease, oncology, and rare disease. Welcome to the team, Monica!

At at the Morgan Stanley Global Healthcare Conference, members of the Lakefront team engaged in productive meetings with colleagues across the industry. Thanks to Morgan Stanley for hosting us. Listen to the fireside chat replay here: event.webcasts.com/starthere…

We're thrilled to welcome Richie Livingston to Lakefront as Director, Investor Relations. Richie brings strong healthcare consulting experience, having worked with large health systems to strengthen financial performance and drive lasting operational improvements. His analytical rigor, cross-functional collaboration, and healthcare sector perspective are a valuable addition to the Lakefront team. Welcome, Richie!

Please join us in welcoming Youssef Toubouti to Lakefront Biotherapeutics as Senior Director, Biometrics. Youssef brings more than 20 years of experience in clinical development across neuroscience, oncology, and ophthalmology, including more than a decade leading Biostatistics and Statistical Programming. His expertise spans clinical trial design, statistical methodology, and regulatory submissions. At Lakefront, Youssef will lead our Biometrics function, overseeing Biostatistics, Data Management, and Statistical Programming. Welcome to the team, Youssef!

Press Release | Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference Join us for a fireside chat on Tuesday, September 15 at 5:35 p.m. ET in New York City on the company's strategy and next phase of growth. A live webcast and replay will be available on our website: lakefrontbio.com/webcasts-ev… Read more: lakefrontbio.com/press-relea…

Lakefront Team Spotlight: Ruth Lan, Vice President, Research and Translation Ruth joined Lakefront through the Ouro Medicines transaction and leads our research and translational efforts. She brings more than 15 years of experience across immunology, immuno-oncology, and translational science. In this Team Spotlight, Ruth shares her perspective on translational research and what makes scientific teams successful. Thanks for your insights, Ruth! #LKFT #Leadership #Biotech

Press Release | U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus Read more: lakefrontbio.com/press-relea…

New preclinical research from scientists at Ouro Medicines and KeyMed Biosciences has been published in mAbs. The research focuses on Lakefront’s lead asset, gamgertamig, which is now being evaluated in partnership with Gilead in clinical studies across multiple autoimmune indications. In preclinical models, researchers observed potent, target-dependent activity and broad B-cell depletion, supporting further development in autoimmune diseases. Read the paper and explore our scientific publications: lakefrontbio.com/innovation/…

We're thrilled to welcome Jeroen De Schauwer to Lakefront Biotherapeutics as Head of Legal Operations EU & Corporate Secretary. Jeroen brings extensive experience in corporate governance, compliance, and legal operations. His expertise will support Lakefront's continued growth and help strengthen our corporate governance and legal operations across Europe. Welcome to the team, Jeroen!

Press Release | Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update Read more in our press release: lakefrontbio.com/press-relea…

The Lakefront team continues to grow. Dusanka Jaksic has joined our Finance Team as Senior Director, Lead FP&A, Corporate Controlling and Head of Internal Control. Dusanka brings more than 20 years of experience in corporate finance. Her extensive background will be instrumental as we advance our pipeline of novel therapeutics. Welcome to the team, Dusanka!

Press Release | Lakefront Appoints Eric Hedrick, MD as Chief Medical Officer. Read more: lakefrontbio.com/press-relea…

We are thrilled to welcome the talented and accomplished Ouro Medicines team to Lakefront. This collaboration brings a clinically meaningful, high‑potential asset and three exciting, early-stage programs into our portfolio. We are excited to get to work together.

Press Release | Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update Galapagos will host a conference call and webcast presentation May 7, 2026, at 14:00 CET / 8:00 am ET. Read more in our press release: glpg.com/press-releases/gala…

We're pleased to share that today our shareholders approved our proposal to change our name to Lakefront Biotherapeutics, effective May 8th. Read more: glpg.com/press-releases/gala…

Press Release | Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases. Read more in our press release: bit.ly/4s33hyo